Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
9-valent pneumococcal conjugate vaccine
- Development stage
- Phase 2
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
A pneumococcal conjugate vaccine designed to provide protection against 9 serotypes of Streptococcus pneumoniae. Pneumococcal conjugate vaccines are used to prevent invasive pneumococcal disease and pneumonia caused by specific serotypes of pneumococcal bacteria.
- Other names
- 9-valent CRM197-conjugated pneumococcal vaccine9-valent pneumococcal conjugate vaccine (PNCRM9)
02
Targets
BCR-PnCPS9 (B cell receptors recognizing capsular polysaccharide epitopes of nine Streptococcus pneumoniae serotypes)TCR-CRM197 (CRM197-specific T-cell receptor)
Beyond the preview
Go deeper on 9-valent pneumococcal conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 9-valent pneumococcal conjugate vaccine.